Cyclerion Therapeutics Inc (CYCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.173x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.18 Million) by net assets ($6.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cyclerion Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cyclerion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarytogan Graphite Ltd
AU:SGA
|
0.039x |
|
Ata Gayrimenkul Yatirim Ortakligi AS
IS:ATAGY
|
0.003x |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
-1.671x |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
-0.116x |
|
Vogiatzoglou Systems S.A
AT:VOSYS
|
0.047x |
|
J-Star Holding Co., Ltd. Ordinary Shares
NASDAQ:YMAT
|
-0.183x |
|
Seamless Distribution Systems AB
ST:SDS
|
-0.126x |
|
Asia Sejahtera Mina Tbk
JK:AGAR
|
0.095x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Cyclerion Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.09 Million | $-3.31 Million | -0.365x | +25.50% |
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular d… Read more